AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

JAZZ · NASDAQ · Biotechnology

Jazz Pharmaceuticals

Develops rare-disease medicines across sleep, epilepsy and oncology.

$244.54

After-hours close+0.06 (+0.02%)

At close$244.48(−2.64%)

Something off on this page? Send us feedback.

Profile

Jazz Pharmaceuticals plcJAZZHealth Care

Develops rare-disease medicines across neuroscience and oncology. Revenue comes from oxybate-based sleep treatments, Epidiolex/Epidyolex for rare epilepsies, and a growing set of cancer therapies, with commercialization shaped by regulatory approvals, payer coverage, supply continuity, and generic competition in high-sodium oxybate.

Develops and commercializes medicines for rare diseases across neuroscience and oncology, with sleep and epilepsy franchises alongside a growing group of cancer therapies. Xywav and Xyrem anchor oxybate-based sleep medicine, while Epidiolex/Epidyolex treats rare epilepsies.

Brings acquired, licensed and internally developed products into shared commercial capabilities. Oncology brands include Rylaze/Enrylaze, Zepzelca, Defitelio/defibrotide, Vyxeos, Ziihera and Modeyso, and the portfolio reaches patients internationally from an Irish headquarters.

Depends on continued commercialization of Xywav and Epidiolex/Epidyolex, successful oncology launches and development, regulatory approvals and post-approval commitments, payer coverage, and reliable manufacturing and supply. High-sodium oxybate also faces generic competition.

Company facts

CEORenée D. Galá

ListedJan 18, 2012

ExchangeNASDAQ

HeadquartersDublin, Ireland

CountryIreland

Employees2,890

CIK0001232524

ISINIE00B4Q5ZN47

Key statistics

Market cap$15.36B

EPS (ttm)$14.63

P/E (ttm)16.71

ROE21.4%

P/B3.22

P/S3.34

Dividend yield—

Beta0.49vs XLV 0.68

Year to date +41.2% · Average volume (30d) 968.5K

Analysts

Price target, next 12 months$299.50+22.5%Median of 48 analysts · vs the Aug 28 close

ConsensusBuy43 of 48 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $244.54

High$322.00+31.7%

Median$299.50+22.5%

Low$229.00−6.4%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 28, 2026	RBC Capital	Target		$277	$299
Aug 26, 2026	RBC Capital	Reiterate	Outperform	$194	$277
Aug 26, 2026	Truist Financial	Target		$300	$281
Aug 26, 2026	Morgan Stanley	Reiterate	Overweight	$283	$322
Aug 26, 2026	Needham	Reiterate	Buy	$292	$310

Earnings

EPS

Estimate$6.47

ReportedDue Nov 4, 2026

Revenue

Estimate$1.21B

ReportedDue Nov 4, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 3, 2026Q2 FY26	$6.18	$5.71	−7.6%	$1.11B	$1.21B	+8.4%	+3.99%
May 5, 2026Q1 FY26	$4.67	$6.34	+35.8%	$978.7M	$1.07B	+9.2%	+7.68%
Feb 24, 2026Q4 FY25	$6.52	$6.64	+1.8%	$1.17B	$1.20B	+2.8%	+13.23%
Nov 5, 2025Q3 FY25	$5.95	$8.13	+36.6%	$1.11B	$1.13B	+1.3%	−2.31%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$897.8M	$1.05B	$1.13B	$1.20B	$1.07B	$1.21B
Gross profit	$793.2M	$929.4M	$868.3M	$1.17B	$762.5M	$1.09B
Operating income	−$55.9M	−$686.4M	$57.5M	$909.2M	$213.8M	$248.2M
Net income	−$92.5M	−$718.5M	$251.4M	$203.5M	$293.1M	$192.8M
Diluted EPS	−$1.52	−$11.74	$4.08	$3.34	$4.43	$2.78
Gross margin	88.3%	88.9%	77.1%	97.9%	71.3%	90.4%
Operating margin	-6.2%	-65.6%	5.1%	75.9%	20.0%	20.5%

Fiscal years (4-quarter sums)FY21 $3.09B · FY22 $3.66B · FY23 $3.83B · FY24 $4.07B · FY25 $4.27B

Revenue by product · Q2 FY26

Xywav$471.2M · 41%

Epidiolex/Epidyolex$292.1M · 25%

Zepzelca$105.8M · 9%

Rylaze/Enrylaze$99.5M · 9%

Defitelio/Defibrotide$62.0M · 5%

High Sodium AG Oxybate Product Royalty Revenue$42.2M · 4%

Vyxeos$31.4M · 3%

Xyrem$30.5M · 3%

Ziihera$15.4M · 1%

Other Royalty And Contract Revenues$10.0M · 1%

Revenue by geography · Q2 FY26

United States$1.08B · 89%

Europe$97.4M · 8%

Other Countries$33.0M · 3%

Balance sheet, Jun 30, 2026Cash & short-term investments $2.20B · Total debt $4.41B · Total assets $11.08B · Shareholders' equity $4.80B

Dividends

No dividends on record.

Ownership

Institutions 128.14%Insiders 3.53%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 62.82M · Float 61.98M · 98.7% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	5.97M	9.50%	13F	Aug 7, 2026
FMR LLC	4.61M	7.34%	13F	Aug 13, 2026
Vanguard Portfolio Management LLC	3.04M	4.83%	13F	Aug 13, 2026
Vanguard Capital Management LLC	2.73M	4.35%	13F	Aug 13, 2026
Capital World Investors	2.70M	4.29%	13F	Aug 12, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 3, 2026	Bruce C. Cozadd	director	−6,000	$252.98
Jul 1, 2026	Bruce C. Cozadd	director	−6,000	$240.47
Jun 15, 2026	Mark Douglas Smith	director	−1,157	$230.55
Jun 10, 2026	Neena M. Patil	officer: EVP & Chief Legal Officer	−1,200	$231.83
May 28, 2026	Samantha Pearce	officer: EVP, Chief Commercial Officer	−6,907	$235.41